AXA1125

AXA1125
Combination of
LeucineAmino acid
IsoleucineAmino acid
ValineAmino acid
ArginineAmino acid
GlutamineAmino acid
N-AcetylcysteineAmino acid derivative
Clinical data
Other namesLIVRQNac
Chemical and physical data
3D model (JSmol)
  • N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N(C(=O)C)[C@@]([H])(CS)C(=O)O
  • InChI=1S/C33H60N10O9S/c1-8-18(6)26(42-27(46)20(34)14-16(2)3)30(49)41-25(17(4)5)29(48)39-21(10-9-13-38-33(36)37)28(47)40-22(11-12-24(35)45)31(50)43(19(7)44)23(15-53)32(51)52/h16-18,20-23,25-26,53H,8-15,34H2,1-7H3,(H2,35,45)(H,39,48)(H,40,47)(H,41,49)(H,42,46)(H,51,52)(H4,36,37,38)/t18-,20-,21-,22-,23-,25-,26-/m0/s1
  • Key:NFSGAYYZQFGPLX-LVYWIKMTSA-N

AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models". It was studied as a treatment for non-alcoholic fatty liver disease and long COVID.[1][2][3][4]

AXA1125 is a fixed composition comprising five amino acids (leucine, isoleucine, valine, arginine, and glutamine) and an amino acid derivative (N-acetylcysteine).[5]

References

  1. ^ Harrison, Stephen A.; Baum, Seth J.; Gunn, Nadege T.; Younes, Ziad H.; Kohli, Anita; Patil, Rashmee; Koziel, Margaret J.; Chera, Harinder; Zhao, Jeff; Chakravarthy, Manu V. (December 2021). "Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease". The American Journal of Gastroenterology. 116 (12): 2399–2409. doi:10.14309/ajg.0000000000001375. ISSN 0002-9270. PMC 8631161. PMID 34382947.
  2. ^ Finnigan, Lucy E.M.; Cassar, Mark Philip; Koziel, Margaret James; Pradines, Joel; Lamlum, Hanan; Azer, Karim; Kirby, Dan; Montgomery, Hugh; Neubauer, Stefan; Valkovič, Ladislav; Raman, Betty (May 2023). "Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study". eClinicalMedicine. 59 101946. doi:10.1016/j.eclinm.2023.101946. PMC 10102537. PMID 37223439.
  3. ^ Park, Brian. "Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis." Medical Bag, 16 Feb. 2022, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A693790920/HRCA?u=anon~8aede0d3&sid=googleScholar&xid=1e146086. Accessed 3 Dec. 2023.
  4. ^ "Axcella antes up in key liver diseases with EMM (endogenous metabolic modulator) compositions". Retrieved 3 December 2023.
  5. ^ Daou, Nadine; Viader, Andreu; Cokol, Murat; Nitzel, Arianna; Chakravarthy, Manu V.; Afeyan, Raffi; Tramontin, Tony; Marukian, Svetlana; Hamill, Michael J. (2021). "A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models". Scientific Reports. 11 (1): 11861. Bibcode:2021NatSR..1111861D. doi:10.1038/s41598-021-88913-1. PMC 8178416. PMID 34088912.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.